Definium Therapeutics (DFTX) Return on Capital Employed (2022 - 2026)
Definium Therapeutics (DFTX) posted quarterly Return on Capital Employed of 56.94% for Q1 2026, down 1285.0% year-over-year from 4.81% in Q1 2025, and up 6.93% quarter-over-quarter from 61.19% in Q4 2025.
Definium Therapeutics (DFTX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Return on Capital Employed for 5 consecutive years, with 56.94% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1285.0% year-over-year to 56.94%; the TTM figure through Mar 2026 stood at 56.94% (down 1285.0% YoY), while the FY2025 annual figure was 54.63%, up 492.0% from the prior year.
- Return on Capital Employed improved to 56.94% in Q1 2026 per DFTX's latest filing, from 61.19% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.93% in Q3 2024 and bottomed at 93.12% in Q4 2023.
- Historically, Return on Capital Employed has averaged 58.25% across 5 years, with a median of 56.11% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 5102 bps — and 2024, when it jumped 5493 bps.
- Definium Therapeutics' Return on Capital Employed stood at 42.1% in 2022, then tumbled by 121 bps to 93.12% in 2023, then surged by 59 bps to 38.19% in 2024, then tumbled by 60 bps to 61.19% in 2025, then advanced by 7 bps to 56.94% in 2026.
- Business Quant data shows DFTX's Return on Capital Employed at 56.94% in Q1 2026, 61.19% in Q4 2025, and 81.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | -37.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.93% |
| Mar 31, 2026 | -56.94% |
| Dec 31, 2025 | -61.19% |
| Sep 30, 2025 | -81.47% |
| Jun 30, 2025 | -56.11% |
| Mar 31, 2025 | -44.09% |
| Dec 31, 2024 | -38.19% |
| Sep 30, 2024 | -35.93% |
| Jun 30, 2024 | -39.34% |
| Mar 31, 2024 | -70.65% |
| Dec 31, 2023 | -93.12% |
| Sep 30, 2023 | -77.32% |
| Jun 30, 2023 | -71.19% |
| Mar 31, 2023 | -49.54% |
| Dec 31, 2022 | -42.10% |
| Sep 30, 2022 | -53.20% |
| Jun 30, 2022 | -52.46% |
| Mar 31, 2022 | -67.45% |